Literature DB >> 32678923

Abnormal epiphyseal development in a feline model of Sandhoff disease.

Margaret A McNulty1,2, Patricia B Prevatt3,4, Elizabeth R Nussbaum5, Ashley N Randle6, Aime K Johnson4,6, Judith A Hudson6, Heather L Gray-Edwards4, Miguel Sena-Esteves7, Douglas R Martin3,4, Cathy S Carlson5.   

Abstract

Sandhoff disease (SD) is caused by decreased function of the enzyme β-N-acetylhexosaminidase, resulting in accumulation of GM2 ganglioside in tissues. Neural tissue is primarily affected and individuals with the infantile form of the disease generally do not survive beyond 4 years of age. Current treatments address neurometabolic deficits to improve lifespan, however, this extended lifespan allows clinical disease to become manifest in other tissues, including the musculoskeletal system. The impact of SD on bone and joint tissues has yet to be fully determined. In a feline model of infantile SD, animals were treated by intracranial injection of adeno-associated virus vectors to supply the central nervous system with corrective levels of hexosaminidase, resulting in a twofold to threefold increase in lifespan. As treated animals aged, signs of musculoskeletal disease were identified. The present study characterized bone and joint lesions from affected cats using micro-computed tomography and histology. All affected cats had similar lesions, whether or not they were treated. SD cats displayed a significant reduction in metaphyseal trabecular bone and markedly abnormal size and shape of epiphyses. Abnormalities increased in severity with age and appear to be due to alteration in the function of chondrocytes within epiphyseal cartilage, particularly the articular-epiphyseal complex. Older cats developed secondary osteoarthritic changes. The changes identified are similar to those seen in humans with mucopolysaccharidoses. Statement of clinical significance: the lesions identified will have significant implications on the quality of life of individuals whose lifespans are extended due to treatments for the primary neurological effects of SD.
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals LLC.

Entities:  

Keywords:  animal models; bone development; chondrocytes; gangliosidosis; growth plate

Mesh:

Year:  2020        PMID: 32678923      PMCID: PMC8241401          DOI: 10.1002/jor.24803

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  28 in total

1.  Sustained normalization of neurological disease after intracranial gene therapy in a feline model.

Authors:  Victoria J McCurdy; Aime K Johnson; Heather L Gray-Edwards; Ashley N Randle; Brandon L Brunson; Nancy E Morrison; Nouha Salibi; Jacob A Johnson; Misako Hwang; Ronald J Beyers; Stanley G Leroy; Stacy Maitland; Thomas S Denney; Nancy R Cox; Henry J Baker; Miguel Sena-Esteves; Douglas R Martin
Journal:  Sci Transl Med       Date:  2014-04-09       Impact factor: 17.956

2.  Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.

Authors:  V J McCurdy; H E Rockwell; J R Arthur; A M Bradbury; A K Johnson; A N Randle; B L Brunson; M Hwang; H L Gray-Edwards; N E Morrison; J A Johnson; H J Baker; N R Cox; T N Seyfried; M Sena-Esteves; D R Martin
Journal:  Gene Ther       Date:  2014-12-04       Impact factor: 5.250

3.  Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.

Authors:  Albert Ruzo; Sara Marcó; Miquel García; Pilar Villacampa; Albert Ribera; Eduard Ayuso; Lucca Maggioni; Federico Mingozzi; Virginia Haurigot; Fatima Bosch
Journal:  Hum Gene Ther       Date:  2012-10-17       Impact factor: 5.695

4.  The pathology of feline GM2 gangliosidosis.

Authors:  L C Cork; J F Munnell; M D Lorenz
Journal:  Am J Pathol       Date:  1978-03       Impact factor: 4.307

5.  Enzyme replacement therapy in a murine model of Morquio A syndrome.

Authors:  Shunji Tomatsu; Adriana M Montaño; Amiko Ohashi; Monica A Gutierrez; Hirotaka Oikawa; Toshihiro Oguma; Vu Chi Dung; Tatsuo Nishioka; Tadao Orii; William S Sly
Journal:  Hum Mol Genet       Date:  2007-12-03       Impact factor: 6.150

6.  Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment.

Authors:  Roberto Giugliani; Andressa Federhen; Maria Verônica Muñoz Rojas; Taiane Vieira; Osvaldo Artigalás; Louise Lapagesse Pinto; Ana Cecília Azevedo; Angelina Acosta; Carmen Bonfim; Charles Marques Lourenço; Chong Ae Kim; Dafne Horovitz; Denize Bonfim; Denise Norato; Diane Marinho; Durval Palhares; Emerson Santana Santos; Erlane Ribeiro; Eugênia Valadares; Fábio Guarany; Gisele Rosone de Lucca; Helena Pimentel; Isabel Neves de Souza; Jordão Correa; José Carlos Fraga; José Eduardo Goes; José Maria Cabral; José Simionato; Juan Llerena; Laura Jardim; Liane Giuliani; Luiz Carlos Santana da Silva; Mara L Santos; Maria Angela Moreira; Marcelo Kerstenetzky; Márcia Ribeiro; Nicole Ruas; Patricia Barrios; Paulo Aranda; Rachel Honjo; Raquel Boy; Ronaldo Costa; Carolina Souza; Flavio F Alcantara; Silvio Gilberto A Avilla; Simone Fagondes; Ana Maria Martins
Journal:  Genet Mol Biol       Date:  2010-12-01       Impact factor: 1.771

7.  AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system.

Authors:  Hannah E Rockwell; Victoria J McCurdy; Samuel C Eaton; Diane U Wilson; Aime K Johnson; Ashley N Randle; Allison M Bradbury; Heather L Gray-Edwards; Henry J Baker; Judith A Hudson; Nancy R Cox; Miguel Sena-Esteves; Thomas N Seyfried; Douglas R Martin
Journal:  ASN Neuro       Date:  2015-04-13       Impact factor: 4.146

Review 8.  Animal models of GM2 gangliosidosis: utility and limitations.

Authors:  Cheryl A Lawson; Douglas R Martin
Journal:  Appl Clin Genet       Date:  2016-07-20

Review 9.  Genetics and Therapies for GM2 Gangliosidosis.

Authors:  Maria Begona Cachon-Gonzalez; Eva Zaccariotto; Timothy Martin Cox
Journal:  Curr Gene Ther       Date:  2018       Impact factor: 4.391

10.  Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses.

Authors:  Hsiang-Yu Lin; Shou-Chuan Shih; Chih-Kuang Chuang; Ming-Ren Chen; Dau-Ming Niu; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2013-05-11       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.